|
Resverlogix Confirms Interim Filings on SEDAR
|
3
|
Resverlogix Corp.
|
Oct 02, 2020 06:35PM
|
|
Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions
|
3
|
Resverlogix Corp.
|
Sep 28, 2022 04:20PM
|
|
Resverlogix Commences Dosing in Phase 3 Clinical Trial BETonMACE
|
2
|
Resverlogix Corp.
|
Nov 11, 2015 11:47AM
|
|
Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International AD/PD Conference
|
6
|
Resverlogix Corp.
|
Apr 01, 2019 11:08AM
|
|
Resverlogix Closes US$30 Million Loan
|
2
|
Resverlogix Corp.
|
May 07, 2018 07:10AM
|
|
Resverlogix Closes $6.6 Million Private Placement with Shenzhen Hepalink
|
3
|
Resverlogix Corp.
|
Jan 31, 2019 06:07PM
|
|
Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
4
|
Resverlogix Corp.
|
Mar 24, 2020 12:59PM
|
|
Resverlogix Biotech Showcase 2017 Slides
|
1
|
Resverlogix Corp.
|
Jan 09, 2017 05:10PM
|
|
Resverlogix BIO CEO & Investor Conference 2017 Slides
|
2
|
Resverlogix Corp.
|
Feb 14, 2017 02:02PM
|
|
Resverlogix Announces Voting Results from the 2020 Meeting of Shareholders and Update on $13 Million Investment by Sheikh Abdulgader Aboud Baeshen
|
4
|
Resverlogix Corp.
|
Dec 23, 2020 04:06PM
|
|
Resverlogix Announces US$30 Million Loan Commitment Letter
|
3
|
Resverlogix Corp.
|
Apr 11, 2018 08:25AM
|
|
Resverlogix Announces US$12 Million Debenture Financing and Full Repayment of Loan
|
2
|
Resverlogix Corp.
|
Sep 27, 2019 09:41AM
|
|
Resverlogix Announces Two New Publications on Apabetalone in Kidney Disease
|
4
|
Resverlogix Corp.
|
Mar 28, 2018 07:29AM
|
|
Resverlogix Announces TSX Review Update
|
2
|
Resverlogix Corp.
|
Apr 12, 2018 08:49AM
|
|
Resverlogix Announces Topline Results in BETonMACE Phase 3 Epigenetics Trial
|
1
|
Resverlogix Corp.
|
Sep 30, 2019 07:33AM
|
|
Resverlogix Announces Third Positive Recommendation From DSMB For Phase 3 BETonMACE
|
1
|
Resverlogix Corp.
|
Mar 17, 2017 08:38AM
|
|
Resverlogix Announces Sixth Positive Recommendation From DSMB For Phase 3 Study of Apabetalone
|
1
|
Resverlogix Corp.
|
Feb 26, 2018 09:44AM
|
|
Resverlogix Announces Seventh Positive Recommendation From The Data Safety Monitoring Board For Phase 3 Study of Apabetalone
|
3
|
Resverlogix Corp.
|
Aug 07, 2018 07:12AM
|
|
Resverlogix Announces Publication on Apabetalone in High-Impact American Journal of Respiratory and Critical Care Medicine (AJRCCM)
|
2
|
Resverlogix Corp.
|
May 06, 2019 09:12AM
|
|
Resverlogix Announces Publication on Apabetalone in Clinical Epigenetics
|
6
|
Resverlogix Corp.
|
Jul 15, 2019 09:19AM
|
